Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 05/01/2017

    HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases

    HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-gmbh-raises-9-million-in-a-series-a-financing-to-develop-kinase-inhibitors-for-the-treatment-of-acute-and-chronic-li
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines – a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology. The development of much-needed vaccines against many other…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Article - 04/07/2016 The schematic shows how oesophageal cells develop into the two major types of oesophageal cancer.

    Epigenetic modifications for the treatment of oesophageal cancer

    Oesophageal cancer is a rare but highly aggressive type of cancer with a rather poor prognosis. Dr. Theresa Ahrens, a researcher in a group led by Prof. Dr. Silke Laßmann and Prof. Dr. Martin Werner at the Institute of Clinical Pathology at the Freiburg University Medical Centre, has tested a variety of epigenetic drugs that can interfere with the development of oesophageal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modifikation-epigenetic-modifications-for-the-treatment-of-oesophageal-cancer-als-therapie-bei-speiseroehrenkrebs
  • Article - 25/04/2016 Trumpp_Andreas.jpg

    Pancreatic cancer and its resistance to therapy

    Pancreatic tumours are among the cancers with the worst prognosis. In many cases they are resistant to treatment. Prof. Dr. Andreas Trumpp and his colleagues from the DKFZ and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM have discovered that the reason why some pancreatic tumours are so resistant to treatment is down to larger quantities of the enzyme CYP3A5 in subtypes of pancreatic cancer. Molecular…

    https://www.gesundheitsindustrie-bw.de/en/article/news/pancreatic-cancer-and-its-resistance-to-therapy
  • Article - 10/03/2014 The photo shows a 3D diagram of a chorismatase enzyme.

    From structure to mechanism

    Life would be impossible without the broad range of enzymes that enable the flow of cellular metabolites in plant, animal and microbial organisms. Enzymes are biocatalysts that control and facilitate difficult chemical reactions associated with inheritance, breathing and digestion as well as the synthesis of natural products. Enzymes like chorismatase have long been attractive drug discovery targets. Junior professor Dr. Jennifer Andexer from the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/from-structure-to-mechanism
  • Press release - 21/01/2008

    Micro-biolytics GmbH - Top spectroscopy technology for the pharmaceutical industry

    Micro-biolytics GmbH now based in the Esslingen-based Life Science Centre develops and produces microsystems solutions for bioanalytical issues. With the support of networks micro-biolytics is hoping to considerably expand its activities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/micro-biolytics-gmbh-top-spectroscopy-technology-for-the-pharmaceutical-industry
  • Article - 07/12/2017 Screenshot showing the separation of biomolecules. Coloured lines or peaks represent different components: antibody (pink), contaminated with lysozyme (dark blue) and myoglobin (light blue).

    GoSilico: a formula for the industrial purification of biomolecules

    “Stop experimenting – GoSilico” is the motto of a young start-up company from Karlsruhe. The founding team of GoSilico GmbH is causing a furore with a simulation software that would make many laboratory experiments obsolete. The chromatographic separation of biomolecules from organisms, samples and cell cultures can be reliably simulated after just a few starter experiments. This saves time, work, material and costs in pharmaceutical development.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gosilico-a-formula-for-the-industrial-purification-of-biomolecules
  • Press release - 26/03/2009 08265_de.jpg

    Sygnis Pharma AG increases capital

    SYGNIS Pharma AG reported its financial results for the first nine months of the fiscal year 20082009. The company improved its cash position significantly as a result of a successful capital increase. Following the capital increase the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to approximately 44.90 of the total share capital. The preparations for the phase II efficacy trial of its lead candidate AX200 in acute ischemic stroke…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-pharma-ag-increases-capital
  • Article - 14/02/2018 The photo shows the biologist in front of the microscope with cell cultures in pink culture medium.

    Animal-free diabetes research with the pancreas chip

    Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/animal-free-diabetes-research-with-the-pancreas-chip
  • Article - 28/03/2019 The IT expert sitting at a meeting table.

    Supporting the human use of artificial intelligence

    Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible.

    https://www.gesundheitsindustrie-bw.de/en/article/news/supporting-the-human-use-of-artificial-intelligence
  • Article - 28/10/2013 Group photo taken in the life sciences research building at the University of Ulm. The photo shows the founders of the UPEP - Ulm Centre for Peptide Pharmaceuticals - together with the University's Dean of the Medical Faculty and the President.

    Peptides as drugs – researchers from Ulm hope to unearth the treasures of the human body

    The human body harbours unsuspected resources. It also produces customised drugs such as peptides. Although this sounds like a far too bold hypothesis, it is not. Researchers from Ulm consider the approach so promising that they have now established the Ulm Centre for Peptide Pharmaceuticals (UPEP).

    https://www.gesundheitsindustrie-bw.de/en/article/news/peptides-as-drugs-researchers-from-ulm-hope-to-unearth-the-treasures-of-the-human-body
  • Article - 17/05/2016 Schematic of the entire chip and an amplified sector showing the central area of the square chip along with the round seeding areas and microchannels.

    Innovative biochip for discovering drugs for treating neuronal conditions

    Parkinson’s, Alzheimer’s and epilepsy are three prominent examples of neuronal conditions (disorders affecting the nerve cells) for which drugs for treatment are intensively sought. Paolo Cesare from the NMI in Reutlingen has developed an innovative 3D system for testing drugs that does not require animal testing. In 2015, the MEAFLUIT system was awarded first prize in BioRegio STERN Management GmbH's Science2Start idea competition.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-biochip-for-discovering-drugs-for-treating-neuronal-conditions
  • Trenzyme GmbH - 20/05/2020 Coronavirus im Elektronenmikroskop

    The SARS-CoV spike protein and its receptor

    The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-sars-cov-spike-protein-and-its-receptor
  • Dossier - 25/03/2013 19401_de.jpg

    Biotechnology goes automated

    Processes that previously required pipetting analysis and production to be carried out manually are increasingly now controlled by automated systems. However this has not necessarily involved a complete reinvention of the wheel instead automation systems used in the plant construction and mechanical engineering sectors are being adapted and optimised for application in the life sciences.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-goes-automated
  • Press release - 01/11/2008 Portrait of Dr. Christine Kranz und Prof. Dr. Boris Mizaikoff

    Boris Mizaikoff and Christine Kranz – on the way to systems analytics

    The two chemists Boris Mizaikoff and Christine Kranz have a great deal in common they are married to each other they have children together and they work at the same university on projects that combine technologies and methods to create multifunctional analytical platforms at the Department of Analytical and Bioanalytical Chemistry at Ulm University.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/boris-mizaikoff-and-christine-kranz-on-the-way-to-systems-analytics
  • Press release - 27/08/2018

    Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

    Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-tar
  • Article - 04/04/2011 14053_de.jpg

    FreiBiotics GmbH – new drugs against resistant bacteria

    Bacteria adapt quickly to their environment and also to antibiotics. Many of the antibiotics used to treat bacterial infections have become ineffective as a great many bacteria have become resistant to them. Freiburg-based FreiBiotics GmbH is looking for completely new classes of antimicrobial substances. A screening method that has been developed over the last few years based on biosensors makes the identification of new substance classes more…

    https://www.gesundheitsindustrie-bw.de/en/article/news/freibiotics-gmbh-new-drugs-against-resistant-bacteria
  • Dossier - 11/05/2009 08594_de.jpg

    Diabetes, a danger that is still underestimated

    In 2010 there will be 10 million diabetes patients in Germany and nearly 33 millions in Europe. The diabetes avalanche is rolling and what is Germany doing? So far so little say experts. There is a lot happening at the same time in different places little is evaluated and a lot is lost in the maelstrom of individual interests. The figures are clear The metabolic disease known as diabetes has reached the proportions of a worldwide epidemic. It not…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/diabetes-a-danger-that-is-still-underestimated
  • SICOS BW GmbH - 18/06/2020 SICOS BW ermöglicht zusammen mit dem Höchstleistungsrechenzentrum Stuttgart Unternehmen den Zugang zu Data Analytics, Smart Data und Big Data, KI und Virtual-Reality-Technologie.

    High-performance computing and data analytics to combat coronavirus

    In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.

    https://www.gesundheitsindustrie-bw.de/en/article/news/high-performance-computing-and-data-analytics-to-combat-coronavirus
  • Article - 19/11/2009 Cellzome Logo

    Cellzome - kinase inhibitors for therapy

    Cellzome is a privately-owned biotechnology company which develops new drugs for the treatment of rheumatoid arthritis, multiple sclerosis and chronic inflammatory intestinal diseases at its two company sites in Heidelberg (Germany) and Cambridge (UK).

    https://www.gesundheitsindustrie-bw.de/en/article/news/cellzome-kinase-inhibitors-for-therapy
  • Microfluidics in medical technology - 24/03/2021 Ein Ventil-Modell, das auf einem Block mit elektrischem Anschluss verschweißt ist

    Ultra-compact: valves with shape memory actuators

    Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ultra-compact-valves-shape-memory-actuators
  • Article - 24/05/2017 A small moss plant on a finger.

    Ralf Reski: from moss to humans

    Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
  • Press release - 17/10/2008

    From protein complex to network

    “In order to fully understand an organism, it is necessary to consider it as a whole,” said Dr. Uwe Schulte, biochemist and CEO of Logopharm GmbH in Freiburg. A growing number of scientists hold the same view, and there is a growing inclination to research the big picture. This is reflected in the continuously increasing number of projects looking into systems biology research.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/from-protein-complex-to-network
  • Article - 01/09/2011 15187_de.jpg

    Quality by Design – a paradigm change in bioprocess development

    Bioprocess technology has undergone a fundamental change with regard to the criteria used for validating product quality: around ten years ago, the U.S. Food and Drug Administration (FDA) revised the 1987 process validation guidance and the subsequent establishment of the Process Analytical Technology (PAT) initiative heralded a paradigm change in bioprocess understanding and control. The FDA’s guidance underwent a paradigm shift from what was…

    https://www.gesundheitsindustrie-bw.de/en/article/news/quality-by-design-a-paradigm-change-in-bioprocess-development
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine

Page 3 / 4

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search